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Abstract  
 
Objective: Pancreatic cancers are characterized by dense stroma. To estimate the degree 
of interference by co-existing non-cancerous cells in molecular analyses, we aimed to 
develop a DNA methylation marker that assesses a cancer cell fraction in DNA samples.  
Methods: Microarray data of 22 pancreatic cancer tissues from TCGA and nine non-
cancerous tissues were used for genome-wide screening. 31 surgical tumor samples (10 
intraductal papillary mucinous neoplasms [IPMNs] and 21 pancreatic cancers), 4 normal, 
and 26 non-tumorous samples were used for validation. Gene-specific methylation 
analysis was conducted by bisulfite pyrosequencing.  
Results: Genome-wide screening isolated SIM1, MIR129-2, NR1I2, and HOXB-AS4, as 
specifically methylated in pancreatic cancer cells. Bisulfite pyrosequencing validated that 
one or more of three genes (SIM1, MIR129-2, and NR1I2) were methylated in 22 (71.0%) 
tumor samples (8 IPMNs and 14 cancers), and all showed low levels of methylation in 26 
(86.7%) normal and non-tumorous samples. Therefore, the three genes collectively 
constituted one marker for a pancreatic cancer cell fraction. The cancer cell fraction 
estimated by the marker was highly correlated with that estimated using the KRAS mutant 
allele frequency (R = 0.79).  
Conclusion: The DNA methylation marker is useful to estimate the pancreatic cancer cell 
fraction in DNA samples. 
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Introduction  
 
Pancreatic cancer is a highly lethal disease with few modalities for early diagnosis 
and few effective systematic therapies for advanced cases [1-4]. To develop effective 
diagnostic and therapeutic strategies, a deeper understanding of the underlying molecular 
pathophysiology is needed. What hampers this understanding is the large stromal 
component comprising the bulk of the tumor mass while pancreatic epithelial cells are a 
minor constituent of the mass [5]. The co-existing normal cells can seriously affect the 
results of molecular analyses of pancreatic cancers, such as next-generation sequencing 
and gene expression analyses [6-8]. Thus, accurate estimation of the cancer cell fraction 
in pancreatic tumor samples is a critical step in the molecular analysis of pancreatic 
cancers. 
To estimate the cancer cell fraction in DNA samples, we previously established a 
unique method using cancer cell-specific DNA methylation in esophageal squamous cell 
carcinomas and gastric cancers [9, 10]. The method utilizes a panel of a limited number 
of genes, typically three, specifically methylated in cancer cells and unmethylated in non-
cancerous cells, such as normal epithelial cells, fibroblasts, and blood cells. Therefore, 
the methylation levels of the genes reflect the cancer cell fraction in DNA samples [9]. 
Since DNA methylation can be analyzed in DNA samples, one of the advantages of using 
a DNA methylation marker is that tissue sections or frozen cells are not needed. At the 
same time, DNA methylation patterns are specific to individual cell types and thus to 
individual tissues [11-14], and a panel of genes specific to pancreatic cancers must 
therefore be isolated. 
In this study, we aimed to establish a cancer cell fraction marker based on DNA 
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methylation profiles in pancreatic cancers.  
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Materials and Methods 
 
Pancreatic surgical specimens, blood samples, and pancreatic cancer cell lines 
A total of 60 pancreatic surgical specimens were obtained at Osaka City University 
Hospital from 31 patients (eight intraductal papillary mucinous neoplasm [IPMN] 
patients, 20 pancreatic cancer patients, and three patients with benign pancreatic 
disorders) (Supplementary Table 1). From the 20 patients with pancreatic cancer, 21 
tumor samples and 19 non-tumorous samples were obtained. From the eight patients with 
IPMNs, 10 tumor samples and seven non-tumorous samples were obtained. From the 
three patients with benign disorders, three normal pancreatic tissue samples were 
obtained. In addition, genomic DNA from one normal pancreatic tissue from a healthy 
33-year-old male (D1234188) was purchased (Biochain, Hayward, CA, USA). In total, 
four normal samples (normal tissues from non-cancer individuals), 26 non-tumorous 
samples (normal tissues from cancer and IPMN patients), and 31 tumor samples (10 
IPMNs and 21 pancreatic cancers) were used as pancreatic specimens in this study. 
Eighteen patients (56.3%) were male, and the mean age was 65.3 years (range: 33-87). 
Normal, non-tumorous, and tumor samples were macroscopically harvested from the 
surgical specimens, and stored at -80 °C. The present study was conducted with the 
approval of the Institutional Review Board of the National Cancer Center and Osaka City 
University Hospital. Written informed consent was obtained from all participants. 
Four peripheral leucocyte samples were obtained from four heathy volunteers. Seven 
human pancreatic cancer cell lines (Capan-2, HPAC, HPAF-II, Hs 766T, MIA PaCa-2, 
PANC-1, and BxPC-3) were purchased from the American Type Culture Collection 
(Manassas, VA, USA). Genomic DNA was extracted by the phenol-chloroform and 
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ethanol precipitation method.  
 
Genome-wide DNA methylation analysis  
Genome-wide DNA methylation analysis was performed using an Infinium 
HumanMehylation450 BeadChip array (Illumina, San Diego, CA, USA) as previously 
reported [15]. Additionally, we downloaded HumanMethylation450 data of 22 pancreatic 
cancerous tissues and nine non-cancerous tissues, which were randomly selected from 
184 pancreatic tissue samples available in the TCGA database (Supplementary Table 2). 
The DNA methylation level of an individual probe was obtained as a β value that 
ranged from 0 (unmethylated) to 1 (fully methylated). From all of the 482,421 CpG sites, 
we excluded 11,421 CpG sites on the sex chromosomes and 5,077 CpG sites at genomic 
positions that could not be specified according to the human genome assembly hg 38. The 
remaining 465,923 CpG sites on autosomes were evaluated in this analysis.  
 
Measurement of DNA methylation levels of specific genomic regions   
Gene-specific DNA methylation levels were measured by bisulfite pyrosequencing. 
Bisulfite modification was performed using 1 µg of BamHI-digested genomic DNA as 
previously reported [16]. The modified DNA was suspended in 40 µl of TE buffer, and 
an aliquot of 1µl was used for bisulfite pyrosequencing. A target region was amplified by 
biotinylated primers, as previously reported [17]. The PCR product was annealed to a 0.2 
µM pyrosequencing primer. Pyrosequencing was carried out using the PSQ 96 
Pyrosequencing System (QIAGEN, Valencia, CA, USA), and a methylation level was 
obtained using PSQ Assay Design software (QIAGEN). 
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Somatic mutant allele frequency of KRAS and other cancer-related genes  
Mutation status of KRAS and other cancer-related genes were analyzed by targeted 
deep sequencing using an Ion Proton next-generation sequencer (Thermo Fischer 
Scientific, Waltham, MA, USA) and a panel of genes (291 regions of 55 cancer-related 
genes, covering 48,005 base positions) [18]. A sequence library was prepared by 
multiplex PCR using Ion AmpliSeq Library Kits 2.0 (Thermo Fischer Scientific). A 
sequence variant was considered as a somatic mutation when the variant allele frequency 
was ≥ 3.0% and the variant was found in at least two forward and two reverse reads using 
CLC Genomics Workbench (QIAGEN). Additionally, only single base substitution 
mutations were analyzed, and deletions and insertions were neglected. A KRAS mutation 
was confirmed by conventional Sanger sequencing using primer sets for exon 2 of KRAS 
[19]. 
To estimate the cancer cell fraction, the KRAS mutant allele frequency was doubled 
because a KRAS mutation is a gain-of-function mutation and is present in one of the two 
alleles when copy number alterations are absent [20-23]. 
 
Statistical analysis 
The correlation analysis was performed using the Pearson’s product-moment 
correlation coefficients. The analyses were performed using PASW statistics version 18.0 
(SPSS Japan Inc., Tokyo, Japan).   
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Results 
 
Isolation of genomic regions specifically methylated in pancreatic cancer cells  
Genomic regions specifically methylated in pancreatic cancer cells but unmethylated 
in non-cancerous cells, including normal pancreatic epithelial cells and stromal cells, 
were isolated. Specifically, genome-wide DNA methylation data of peripheral leucocyte 
samples and cell lines were obtained by their beadarray analysis with Infinium Human 
Methylation450, and those of cancerous and non-cancerous pancreatic tissues were 
extracted from The Cancer Genome Atlas (TCGA) database (Supplementary Table 2). 
First, from probes located at 465,923 CpG sites on autosomes, we selected 143,241 CpG 
sites unmethylated (β value ≤ 0.2) in four peripheral leucocyte samples from four healthy 
volunteers and in nine non-cancerous tissues from nine patients (Figure 1). 
We further selected 799 CpG sites methylated in six or more of seven pancreatic 
cancer cell lines (β ≥ 0.8) and in 14 or more of 22 pancreatic cancer tissues (β ≥ 0.3). To 
isolate genomic regions that were highly likely to be specifically methylated, we selected 
those with three or more flanking probes of consistent values, as previously reported [24, 
25], and finally isolated 24 genes corresponding to 29 genomic regions. Alternatively, we 
isolated genomic regions with a higher incidence of methylation but with less chance of 
validation. From the 143,241 CpG sites, we selected 281 CpG methylated sites in all of 
the seven cell lines (β ≥ 0.8) and in 16 or more of the 22 cancer tissues (β ≥ 0.3). To isolate 
genomic regions likely to be specifically methylated, we selected those with two or more 
flanking probes of consistent values, and isolated 27 genes corresponding to 31 genomic 
regions. Nine genes were overlapping in the two algorithms, and 42 genes were finally 
isolated as candidate marker genes (Figure 1 and Supplementary Table 3). 
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Selection of a panel of fraction marker genes with broad coverage across patients  
To select candidate fraction marker genes, we screened genes that showed a low 
frequency of copy number alternations (CNAs), which can influence the methylation 
levels of the genes [26]. From the 42 candidate marker genes, we selected 34 genes with 
low frequencies of CNAs in pancreatic cancers [27, 28] (Supplementary Table 3). Next, 
to identify marker genes methylated in different sets of patients, we conducted a 
hierarchical clustering analysis using the 34 candidate marker genes, and observed four 
second-level clusters (I, II, III, and IV) (Figure 2A). From each of the four second-level 
clusters, we selected genes which had broad coverage across patients and for which we 
successfully designed high-quality primers for bisulfite pyrosequencing (Figure 3). 
Consequently, four genes, namely SIM1, MIR129-2, NR1I2, and HOXB-AS4, met the two 
conditions as candidate marker genes (Table 1, and Supplementary Table 4). As expected, 
the four genes covered different sets of patients and collectively had broad coverages 
across pancreatic cancer patients and cell lines (Figure 2B, and Supplementary Figure 1).  
 
Methylation levels in pancreatic surgical specimens 
To evaluate whether the four candidate marker genes could accurately estimate cancer 
cell fractions, methylation levels of the four genes were validated by bisulfite 
pyrosequencing in 61 pancreatic surgical specimens, consisting of four normal samples, 
26 non-tumorous samples, 10 IPMN samples, and 21 pancreatic cancer samples 
(Supplementary Table 1). Unexpectedly, HOXB-AS4 had relatively high methylation 
levels even in normal samples and non-tumorous samples (11 of 30 with methylation 
levels ≥ 10%) (Supplementary Figure 2). Therefore, excluding HOXB-AS4, we adopted a 
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panel of the remaining three genes, SIM1, MIR129-2, and NR1I2, as the final candidate 
marker genes for pancreatic cancer cell fraction. 
Among the 10 IPMN samples and 21 pancreatic cancer samples, at least one of the 
three genes, SIM1, MIR129-2, and NR1I2, was highly methylated in eight (80.0%) IPMNs 
and 14 (66.7%) pancreatic cancers respectively. At the same time, the three genes had 
little methylation among the four normal samples and 22 of 26 (84.6%) non-tumorous 
samples (Figures 4A and 4B). Among the four non-tumorous samples (20N, 23N, 42N, 
and 60N) with methylation levels ≥ 10%, sample 60N had a high allele frequency of a 
KRAS mutation (Supplementary Table 5). However, in the remaining three samples, 
somatic mutations were not detected in the following mutation analysis (Supplementary 
Tables 5 and 6). Overall, the panel of the three genes, SIM1, MIR129-2, and NR1I2, was 
considered capable of estimating cancer cell fractions with a broad coverage of patients. 
Cancer cell-specific mutations were additionally used to estimate the fraction of 
pancreatic cancer cells. Mutation allele frequencies of 55 cancer-related genes including 
KRAS, which is known to be mutated in approximately 90% of pancreatic cancers [20, 
29-31], were analyzed by target deep sequencing. In the 19 tumor samples with a KRAS 
mutation (seven IPMNs, 12 pancreatic cancers), substantial levels of methylation of the 
fraction marker genes (methylation level ≥ 10%) were also observed in all of them 
(Supplementary Table 5). In the 12 tumor samples without a KRAS mutation (three 
IPMNs, nine pancreatic cancers), two (22T and 23T) had substantial methylation levels 
(24.1% in 22T and 36.2% in 23T) (Figures 4A and 4B). Accordingly, these two samples 
had somatic mutations in other genes (CDKN2A in 22T; ALK, SMO, and CCND1 in 23T), 
confirming that they indeed contained cancer cells (Supplementary Table 6). As discussed 
previously, sample 60N had a variant allele frequency of 4.2 % for a KRAS mutation.  
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Correlation between the cancer cell fraction estimated by the DNA methylation 
marker and that estimated using the KRAS mutant allele frequency  
To assess the accuracy of the cancer cell fraction marker, we evaluated the correlation 
between the cancer cell fraction estimated by the panel of the three DNA methylation 
marker genes and that estimated using the KRAS mutant allele frequency. As shown in 
Figure 5, we found the two to be highly correlated (R = 0.79).  
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Discussion 
 
The pancreatic cancer cell fraction was successfully estimated using a panel of three 
genes, namely SIM1, MIR129-2, and NR1I2, that was extensively selected based upon 
their lack of methylation in non-tumorous samples, their high incidence of methylation 
in tumorous samples, and their broad coverage across different patients. The high 
performance of the panel was shown by a high correlation (R = 0.79) between the cancer 
cell fraction estimated by the panel of DNA methylation marker genes and that estimated 
by the KRAS mutant allele frequency. Notably, the fraction marker was informative not 
only in pancreatic cancers, but also in IPMNs, which are known risk factors for pancreatic 
cancers [32]. Functionally, MIR129-2 is reported to be a tumor-suppressor gene [33, 34], 
having the potential to be a driver gene in pancreatic carcinogenesis. On the other hand, 
neither NR1I2 nor SIM1 were expressed in normal pancreatic tissues, suggesting that they 
are passenger genes.  
The cancer cell fraction can be estimated using the mutant allele frequency obtained 
by next-generation sequencing. Although KRAS mutation is useful for this purpose in 
pancreatic cancers, the DNA methylation marker had a broader coverage across patients. 
As shown in Figure 4A, substantial methylation levels were obtained even in the two 
samples without KRAS mutations (22T and 23T). Importantly, when these two samples 
were included in the analysis of correlation of cancer cell fractions, the correlation 
coefficient remained high (R = 0.79) (Supplementary Figure 3). Furthermore, the fraction 
marker genes were methylated in KRAS-wild-type pancreatic cancer cell lines (Hs 766T 
and BxPC-3) as shown in Figure 2B. Notably, the DNA methylation marker developed 
here detected the presence of pre-malignant cells or cancer cells in a "normal" sample 
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(60N). This sample harbored a KRAS mutation, which can be present in pancreatic cancer 
or pre-malignant cells [35]. 
Furthermore, cancer cell fractions in early-stage pancreatic cancers were successfully 
estimated in eight samples. This suggests that the DNA methylation fraction marker may 
be used for early detection of pancreatic cancers using pancreatic juice or peripheral blood 
samples. Also, the use of cancer cell fraction markers has been reported to improve the 
performance of molecular analyses of cancers. For example, in esophageal squamous cell 
carcinomas, the predictive power of a biomarker was improved after the correction of the 
cancer cell fraction using a similar fraction marker [25]. Moreover, in lung cancers, 
correction of the cancer cell fraction allowed for more accurate estimations of copy 
number alterations from sequencing data [7]. Thus, estimation and correction of 
pancreatic cancer cell fraction will be useful for many aspects of pancreatic cancer 
research.  
The use of DNA methylation for a cancer cell fraction marker has multiple advantages. 
The methylation marker can be used in DNA samples, without the need for histological 
sections and cell counting. In our previous study, we demonstrated that the accuracy of 
estimation of the cancer cell fraction by DNA methylation marker was equivalent to that 
of the pathological measurement [9]. Although the pathological approach has been 
established as the gold standard to estimate the cancer cell fraction, it is time-consuming 
and prone to technical difficulties when distinguishing cancer cells from co-existing 
stromal cells, especially when cancer cells infiltrate their surrounding non-cancerous 
tissue, as is the case with pancreatic cancers [36]. In addition, quantitative methylation 
analysis is much more cost-effective compared with next-generation sequencing, and can 
be useful in cancers without measurable mutations.  
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Three non-tumorous samples (20N, 23N, and 42N) had relatively high levels of 
methylation (≥ 10%), but no evidence of the presence of tumor cells was obtained by 
mutation analysis. Since 6.67% of pancreatic cancers without KRAS mutations have 
mutations of other driver genes [27], there remains a possibility that undetected tumor 
cells were contaminated in these samples as was the case for 60N. 
Some limitations remain in this study. Firstly, the sample number was relatively small. 
Secondly, the sensitivity (71.0%) and specificity (86.7%) of the fraction marker may be 
insufficient for some analyses that require high accuracy. Thirdly, our present criterion 
for the isolation of fraction marker genes might have been too strict. Indeed, although 
BNC1, ADMTS1, and CD1D are reported to be accurate in the detection of pancreatic 
cancers [37, 38], these genes were excluded from the candidate marker genes in this study. 
Specifically, ADMTS1 showed a low incidence of methylation (β > 0.3) in the cancerous 
tissues (0-2 of 22 tissues). Three of the 33 BNC1 probes had a high incidence of 
methylation in cancer tissues (14-18 of 22), and one of the 15 CD1D probes also had a 
high incidence (18 of 22). However, our screening criterion for the methylation of 
consecutive probes hampered isolation of these two genes.  
In conclusion, we established a pancreatic cancer cell fraction marker using DNA 
methylation that can be used in DNA samples. This marker will facilitate a variety of 
molecular analyses of pancreatic cancers by providing an accurate estimation of cancer 
cell fractions in pancreatic tissue samples.   
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Figure legends 
 
Figure 1. Genome-wide isolation of genomic regions specifically methylated in 
pancreatic cancer cells 
The genome-wide DNA methylation data were obtained from i) our own analysis of 
peripheral leucocytes and pancreatic cancer cell lines and ii) the TCGA database 
(cancerous and non-cancerous tissues). Probes unmethylated in non-cancerous cells were 
first selected, and then those methylated in cancer cells were selected using three- and 
two-consecutive-probe approaches. Candidate genomic regions were converted to 
candidate genes, and 24 and 27 genes were selected as candidate fraction markers. Nine 
genes were overlapping in the two approaches, and 42 genes were finally isolated as 
candidate marker genes. 
 
Figure 2. Selection of a panel of fraction marker genes using a hierarchical cluster 
analysis  
(A) A hierarchical cluster analysis was conducted using the 121 CpG sites in 34 genes 
with low frequencies of CNAs and 22 pancreatic cancerous tissues. Consequently, four 
second-level clusters (I, II, III, and IV clusters), as shown by blue bars on the left side, 
were obtained. (B) Four candidate genes (SIM1, MIR129-2, NR1I2, and HOXB-AS4) 
selected from the four second-level clusters in panel A had broad and different coverage 
sets of patients and cancer cell lines. Red and blue cells show samples with β values ≥ 0.3 
and ≥ 0.8, respectively.  
  
Pancreatic cancer cell fraction marker  Ishihara et al. 
24 
 
Figure 3. Genomic structures of the four candidate marker genes 
Genomic structure and the location of a CpG island are shown at the top. A CpG map 
around the target CpG sites is shown in the bottom. Vertical lines show individual CpG 
sites. Arrows show the targeted CpG locations of bisulfite pyrosequencing. The triangle 
shows the CpG site where the methylation level was measured by bisulfite 
pyrosequencing.  
 
Figure 4. Methylation levels of SIM1, MIR129-2, and NR1I2 in pancreatic surgical 
specimens  
Methylation levels of the three marker genes, SIM1, MIR129-2, and NR1I2, were 
validated by bisulfite pyrosequencing using 61 pancreatic surgical specimens. Four 
normal samples, 26 non-tumorous samples, 10 IPMN samples, and 21 pancreatic cancer 
samples were used. Among the three genes, one or more were highly methylated in 22 
tumor samples (eight IPMNs, 14 pancreatic cancers). Samples with a KRAS mutation are 
shown by asterisks. Only a small amount of methylation was detected in the normal and 
non-tumorous samples. (A) Individual methylation levels of the three genes. (B) 
Collective presentation of the highest methylation level among the three genes.  
 
Figure 5. Correlation between the cancer cell fraction estimated by the DNA 
methylation marker and that estimated using the KRAS mutant allele frequency 
The cancer cell fraction estimated by the DNA methylation marker had a high correlation 
with that estimated using the KRAS mutant allele frequency (R = 0.79). Using the KRAS 
mutant allele frequency, the cancer cell fraction was estimated by doubling its frequency.  
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Supplementary Figure legends 
 
Supplementary Figure 1. An analysis of the patient coverage by the four candidate 
marker genes  
A hierarchical clustering analysis was conducted using the four candidate CpG sites (four 
genes) and 22 cancerous samples. The four genes covered all samples (β value ≥ 0.3). 
 
Supplementary Figure 2. Methylation levels of HOXB-AS4 in pancreatic surgical 
specimens 
The methylation level of HOXB-AS4 was validated by bisulfite pyrosequencing using 61 
pancreatic surgical specimens. High methylation levels (≥ 10%) were observed even in 
normal and non-tumorous samples (11 of 30 samples), in contrast with the other three 
genes, SIM1, MIR129-2, and NR1I2. 
 
Supplementary Figure 3. Correlation between the cancer cell fraction estimated by 
the DNA methylation marker and that estimated using the somatic mutant allele 
frequency of KRAS and other cancer-related genes  
The cancer cell fraction estimated by the DNA methylation marker had a high correlation 
with that estimated using the somatic mutant allele frequency of KRAS or other cancer-
related genes (R = 0.79). Using somatic mutations of oncogenes, the cancer cell fraction 
was estimated by doubling their mutant allele frequencies. Black circles show the tumor 
samples with KRAS mutations, the blue triangle shows the 22T sample with a CDKN2A 
mutation, and the red diamond shows the 23T sample with ALK, SMO, and CCND1 
mutations. In the 23T sample, the cancer cell fraction was estimated using the ALK 
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mutation frequency because its frequency was the highest among that of the three genes. 
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Table 1. Candidate genomic regions for fraction markers 
 
No. Gene 
symbol* 
Chr* Nt. number* Probe ID Relation to a 
CpG island 
Position to a TSS* No. of 
consecutive 
probes 
Incidence of 
methylation 
in cell lines 
Incidence of 
methylation in 
cancer tissues 
1 SIM1 6 100465064 cg27252696 Island -1386;-134;-174 3 6 15 
2 MIR129-2 11 43581297 cg14416371 Island 24860;2407;1801;-84 3 7 17 
3 NR1I2 3 119810109 cg00836482 Island 27398;29624;29624;28073;-968 2 7 18 
4 HOXB-AS4 17 48633979 cg01452847 Island 4429;5303;-406;-1419 2 7 21 
*According to human genome assembly hg38. Chr, chromosome; Nt. nucleotide; TSS, transcriptional start site 
Patient ID Sex Age Pathological diagnosis Pathological stage Normal sample Non-tumrous sample Tumor sample 
0 Male 33 Purchased normal pancreatic genomic DNA 1
1 Female 75 Pancreatic cancer (adenocarcinoma) I 1 1
2 Female 63 Pancreatic cancer (adenocarcinoma) III 1 1
3 Female 73 Pancreatic cancer (adenocarcinoma) III 1 1
4 Female 79 Pancreatic cancer (adenocarcinoma) III 1 1
7 Male 78 IPMN 1 1
8 Male 38 IPMN 1 1
9 Male 75 IPMN 1 2*
10 Female 87 Carcinoma drived from IPMN I 1
11 Female 72 Carcinoma drived from IPMN I 1
12 Female 72 Carcinoma drived from IPMN I 1 1
13 Male 57 Chronic pancreatitis 1
16 Male 80 Autoimmunepancreatitis 1
19 Male 40 Chronic pancreatitis 1
20 Male 75 Pancreatic cancer (adenocarcinoma) III 1 1
21 Male 66 Pancreatic cancer (adenocarcinoma) III 1 1
22 Female 69 Pancreatic cancer (adenocarcinoma) III 1 1
23 Female 69 Pancreatic cancer (adenocarcinoma) IV 1 1
26 Male 58 Pancreatic cancer (adenocarcinoma) III 1 1
27 Male 56 Pancreatic cancer (adenocarcinoma) III 1 1
28 Male 67 IPMN 2*
31 Male 74 IPMN 1 1
35 Female 64 Carcinoma drived from IPMN I 1 3*
42 Male 66 Carcinoma drived from IPMN I 1 1
48 Male 55 IPMN 1 1
52 Male 53 Carcinoma drived from IPMN III 1 1
53 Male 78 Carcinoma drived from IPMN I 1 1
60 Female 74 IPMN 1 1
62 Female 68 IPMN 1 1
63 Female 61 Pancreatic cancer (adenocarcinoma) III 1 1
64 Female 67 Pancreatic cancer (adenocarcinoma) IV 1 1
75 Male 46 Pancreatic cancer (adenocarcinoma) IIb 1 1
*Two or three tumor samples were obtained from one patient.
Supplementary Table 1. Patient background for pancreatic surgical specimens
TCGA biospecimen ID Sample Sample ID Sex Age Pathological diagnosis Pathological Stage
TCGA-IB-AAUO Cancerous tissue PA01 Female 64 Adenocarcinoma Ductal Type IIB
TCGA-H8-A6C1 Cancerous tissue PA02 Male 53 Adenocarcinoma-Other Subtype IIA
TCGA-XD-AAUG Cancerous tissue PA03 Female 66 Adenocarcinoma Ductal Type IV
TCGA-LB-A7SX Cancerous tissue PA04 Female 74 Adenocarcinoma Ductal Type IIB
TCGA-3A-A9IU Cancerous tissue PA05 Male 65 Adenocarcinoma Ductal Type IIB
TCGA-3A-A9IB Cancerous tissue PA06 Female 69 Adenocarcinoma Ductal Type IIB
TCGA-HZ-A8P0 Cancerous tissue PA07 Male 76 Adenocarcinoma Ductal Type IIB
TCGA-S4-A8RM Cancerous tissue PA08 Male 67 Adenocarcinoma Ductal Type IIB
TCGA-S4-A8RP Cancerous tissue PA09 Female 77 Adenocarcinoma Ductal Type IIB
TCGA-LB-A9Q5 Cancerous tissue PA10 Female 63 Adenocarcinoma Ductal Type IIB
TCGA-2J-AABP Cancerous tissue PA11 Female 58 Undifferentiated Carcinoma IIB
TCGA-3A-A9IH Cancerous tissue PA12 Female 66 Adenocarcinoma Ductal Type 1A
TCGA-H6-A45N Cancerous tissue PA13 Female 88 Adenocarcinoma-Other Subtype IIB
TCGA-HZ-A9TJ Cancerous tissue PA14 Male 70 Adenocarcinoma-Other Subtype IV
TCGA-2J-AABH Cancerous tissue PA15 Male 61 Adenocarcinoma-Other Subtype IIA
TCGA-FZ-5919 Cancerous tissue PA16 Female 59 Adenocarcinoma Ductal Type IIB  
TCGA-FZ-5920 Cancerous tissue PA17 Male 52 Adenocarcinoma Ductal Type IIB
TCGA-FZ-5922 Cancerous tissue PA18 Male 81 Adenocarcinoma Ductal Type IIA
TCGA-FZ-5923 Cancerous tissue PA19 Male 71 Adenocarcinoma Ductal Type IV
TCGA-FZ-5924 Cancerous tissue PA20 Male 83 Adenocarcinoma Ductal Type IIA
TCGA-FZ-5926 Cancerous tissue PA21 Female 73 Adenocarcinoma Ductal Type III
TCGA-F2-6879 Cancerous tissue PA22 Male 57 Adenocarcinoma-Other Subtype IIB
TCGA-H6-A45N Non-cancerous tissue Female 88 Adenocarcinoma-Other Subtype IIB
TCGA-H6-8124 Non-cancerous tissue Female 56 Adenocarcinoma Ductal Type IIB
TCGA-HV-A5A3 Non-cancerous tissue Male 50 Adenocarcinoma Ductal Type IIA
TCGA-FZ-5919 Non-cancerous tissue Female 59 Adenocarcinoma Ductal Type IIB
TCGA-FZ-5920 Non-cancerous tissue Male 52 Adenocarcinoma Ductal Type IIB
TCGA-FZ-5922 Non-cancerous tissue Male 81 Adenocarcinoma Ductal Type IIA
TCGA-FZ-5923 Non-cancerous tissue Male 71 Adenocarcinoma Ductal Type IV
TCGA-FZ-5924 Non-cancerous tissue Male 83 Adenocarcinoma Ductal Type IIA
TCGA-FZ-5926 Non-cancerous tissue Female 73 Adenocarcinoma Ductal Type III
Supplementary Table 2. Pancreatic tissue sample data extracted from the TCGA database
Supplementary Table 3. Forty-two genes from 45 genomic regions specifically methylated in pancreatic cancer cells.
No. Gene symbol* Chr* Nt. number* Probe ID Relation to a CpG island Position to a TSS*
No. of
consecutive
probe
Incidence of
methylation in cell
lines
Incidence of
methylation in cancer
tissues
Copy number
alternations**
1 RNF220 1 44407392 cg04023150 Island 2197;2103;2103;-1311 3 7 15 Deletion
44407557 cg10224098 Island 2362;2268;2268;-1146 3 7 18
44407920 cg04541474 Island 2725;2631;2631;-783 3 7 14
2 KCNA3 1 110674572 cg20302133 Island 462 3 and 2 7 20 Deletion
110674784 cg26013553 Island 250 3 and 2 7 19
110674875 cg11595545 Island 159 3 and 2 7 20
110674953 cg01423964 Island 81 3 and 2 7 17
110675069 cg06750832 Island -35 3 7 14
3 TIRM58 1 247857134 cg20429172 Island -66 3 6 19 Deletion
247857330 cg20810478 Island 130 3 6 19
247857339 cg26157385 Island 139 3 and 2 7 20
247857390 cg23054189 Island 190 3 and 2 7 20
247857395 cg20146541 Island 195 3 and 2 7 20
247857510 cg07533148 Island 310 3 and 2 7 19
247857789 cg16021909 Island 589 3 and 2 7 19
4 CELF2 10 11017751 cg17290701 Island 12454;-180 3 6 14 None
11017755 cg26328510 Island 12458;-176 3 7 14
11017762 cg03813164 Island 12465;-169 3 7 15
11017764 cg12356890 Island 12467;-167 3 7 15
5 MIR129-2 11 43581297 cg14416371 Island 24860;2407;1801;-84 3 7 17 None
43581307 cg14944647 Island 24870;2417;1811;-74 3 7 14
43581329 cg01939477 Island 24892;2439;1833;-52 3 7 14
43581364 cg16407471 Island 24927;2474;1868;-17 3 and 2 7 16
43581370 cg05376374 Island 24933;2480;1874;-11 3 and 2 7 17
6 GABRG3 15 26970850 cg03024760 Island -595;-544;-433 3 6 14 None
26970861 cg02281208 Island -584;-533;-422 3 6 16
26970865 cg08182446 Island -580;-529;-418 3 6 15
7 SALL1 16 51150875 cg05151154 Island 401;-277;493;367;-277 3 6 15 None
51150975 cg07498275 Island 301;-377;393;267;-377 3 7 14
51151090 cg08806408 Island 186;-492;278;152;-492 3 7 15
8 HOXB-AS3 17 48577927 cg07438617 S_Shore 28296;12312;1431;12315;12309;4696;12346;26986;2185 3 6 14 None
48578025 cg21546671 S_Shore 28394;12214;1333;12217;12211;4598;12248;26888;2087 3 6 15
48578032 cg14458834 S_Shore 28401;12207;1326;12210;12204;4591;12241;26881;2080 3 6 17
48578114 cg15565065 S_Shore 28483;12125;1244;12128;12122;4509;12159;26799;1998 3 6 16
48578199 cg08089301 S_Shore 28568;12040;1159;12043;12037;4424;12074;26714;1913 3 6 17
48578218 cg07015911 S_Shore 28587;12021;1140;12024;12018;4405;12055;26695;1894 3 6 16
48578226 cg09194159 S_Shore 28595;12013;1132;12016;12010;4397;12047;26687;1886 3 6 14
9 GALR1 18 77250010 cg03659519 Island -540 3 6 14 Amplification
77250012 cg20872937 Island -538 3 6 15
77250044 cg17911318 Island -506 3 6 16
10 CHST8 19 33621919 cg26565021 Island -37;-53;-37;-66 3 6 16 None
33622085 cg19594305 Island 129;113;129;100 3 6 17
33622104 cg16190732 Island 148;132;148;119 3 6 17
11 ZNF382 19 36605246 cg25397945 Island -74;428;-90;-68;-68;-83;12;-2;31;17;-2 3 and 2 7 22 None
36605419 cg02587316 Island 99;601;83;105;105;90;-161;-175;-142;-156;-175 3 and 2 7 17
36605421 cg18630667 Island 101;603;85;107;107;92;-163;-177;-144;-158;-177 3 and 2 7 16
36605427 cg05020604 Island 107;609;91;113;113;98;-169;-183;-150;-164;-183 3 7 15
36605585 cg04332534 Island 265;767;249;271;271;256;-327;-341;-308;-322;-341 3 6 15
12 AC003006.7 19 57708927 cg11294513 Island 26881;26881;268;242;26891 2 7 21 None
57709002 cg05661282 Island 26956;26956;193;167;26966 2 7 20
57709148 cg27049766 Island 27102;27102;47;21;27112 3 and 2 7 16
57709289 cg03234186 S_Shore 27243;27243;-94;-120;27253 3 and 2 7 17
57709294 cg08668790 S_Shore 27248;27248;-99;-125;27258 3 and 2 7 16
13 AC093702.1 2 45013869 cg25623768 Island -200 3 6 14 None
45013971 cg22882665 Island -302 3 6 14
45014083 cg10476112 Island -414 3 6 14
14 POU3F3 2 104855502 cg01878345 Island -10;2216 3 7 18 None
104855507 cg17078686 Island -5;2221 3 6 17
104855521 cg24472231 Island 9;2235 3 6 14
104855735 cg05506365 Island 223;2449 3 7 16
15 HOXD-AS2 2 176122734 cg04739647 Island 14280;13;-30 3 7 15 None
176122737 cg05167251 Island 14277;16;-27 3 and 2 7 18
176122877 cg02885007 Island 14137;156;113 3 and 2 7 18
176129634 cg17863912 Island 7380;-107;-61;-724;-389 2 7 16
176129637 cg19384289 Island 7377;-104;-58;-721;-386 2 7 19
176129937 cg15808943 Island 7077;196;242;-421;-86 3 and 2 7 16
176130036 cg24416513 Island 6978;295;341;-322;13 3 and 2 7 18
176130360 cg15520279 Island 6654;619;665;2;337 3 and 2 7 19
16 BHLHE23 20 63007166 cg14060496 Island -130;-130 3 6 15 None
63007222 cg26492446 Island -186;-186 3 7 15
63007236 cg27501878 Island -200;-200 3 7 14
17 PEX5L 3 180036815 cg02119363 Island -44;112;116;145;221;239 3 7 15 None
180036825 cg13473356 Island -54;102;106;135;211;229 3 and 2 7 16
180036827 cg04894619 Island -56;100;104;133;209;227 3 and 2 7 16
18 EVC2 4 5708592 cg14654886 Island 957;-24;957;472 3 and 2 7 18 None
5708610 cg27434509 Island 939;-42;939;454 3 and 2 7 19
5708645 cg17255450 Island 904;-77;904;419 3 6 18
19 FBXL7 5 15500161 cg26134895 Island -36;-1278 3 6 17 None
15500605 cg06577205 Island 408;-834 3 7 18
15500724 cg14667871 Island 527;-715 3 7 15
19a - 5 73299798 cg03638905 Island - 3 7 16 None
73299858 cg12505170 Island - 3 6 17
73299914 cg08893692 Island - 3 7 17
20 SIM1 6 100465030 cg21684012 Island -1352;-100;-140 3 6 14 None
100465064 cg27252696 Island -1386;-134;-174 3 6 15
100465070 cg17380661 Island -1392;-140;-180 3 6 15
21 HOXA10 7 27164433 cg25188395 Island 15581;1098;1094;10748;6066;5305;5012 3 6 18 None
27164730 cg03698009 Island 15284;801;797;10451;5769;5008;4715 3 6 14
27165044 cg20399871 Island 14970;487;483;10137;5455;4694;4401 3 7 15
27165109 cg26476852 Island 14905;422;418;10072;5390;4629;4336 3 7 17
22 VWC2 7 49773437 cg04904331 Island -225 3 6 15 None
49773469 cg14045872 Island -193 3 and 2 7 17
49773492 cg01893212 Island -170 3 and 2 7 16
49773506 cg02467990 Island -156 3 and 2 7 17
49773515 cg09493505 Island -147 3 and 2 7 18
49773890 cg18206027 Island 228 3 and 2 7 18
23 VIPR2 7 159145277 cg23572908 Island -319;-417;-424 3 6 17 Deletion
159145359 cg25189564 Island -401;-499;-506 3 6 19
159145368 cg20673829 Island -410;-508;-515 3 6 17
24 NKX2-6 8 23706412 cg14428146 Island 187;-730 3 7 14 None
23706457 cg15854847 Island 142;-685 3 and 2 7 17
23706495 cg05477514 Island 104;-647 3 and 2 7 17
23706518 cg13324546 Island 81;-624 3 7 16
23706643 cg03694713 Island -44;-499 3 6 15
23706680 cg22747746 Island -81;-462 3 7 16
23706781 cg10603004 Island -182;-361 3 6 17
25 ADAM32 8 39107507 cg22848598 Island -143;-23;-65;-102;-450;-267;516 3 7 14 None
39107603 cg26124318 Island -47;73;31;-6;-354;-171;612 3 7 15
39107733 cg02637318 Island 83;203;161;124;-224;-41;742 3 7 15
25a - 8 56157129 cg02182795 Island - 3 6 14 None
56157348 cg11071231 Island - 3 6 17
56157454 cg16504626 Island - 3 6 14
26 BARHL2 1 90718140 cg11823511 Island -902 2 7 19 Deletion
90718569 cg20311863 Island -1331 2 7 17
27 CCNA1 13 36431926 cg02478448 Island -433;22;-598;405 2 7 18 None
36431970 cg18348647 Island -389;66;-554;449 2 7 17
28 NKX2-1 14 36518096 cg23906738 Island 2133;1598;3054;2039;-1183;1426 2 7 17 None
36518203 cg04347874 Island 2026;1491;2947;1932;-1076;1319 2 7 16
29 CLEC14A 14 38255443 cg16404157 Island 927 2 7 16 None
38255470 cg05057720 Island 900 2 7 17
30 SALRNA1 14 60642089 cg19610529 N_Shore 2872 2 7 17 None
60642489 cg23322933 Island 3272 2 7 16
31 LINC00925 15 89379097 cg09969277 Island 17517;980;996;533;-28;965;16622;1047;9941;16609 2 7 17 Deletion
89379114 cg09086835 Island 17534;997;1013;550;-11;982;16639;1064;9958;16626 2 7 20
32 HOXB-AS4 17 48633979 cg01452847 Island 4429;5303;-406;-1419 2 7 21 None
48634084 cg22851691 S_Shore 4534;5408;-511 2 7 20
33 AC010729.1 2 5696049 cg26659079 Island -172;3381 2 7 17 None
5696099 cg18897632 Island -122;3431 2 7 18
34 TLX2 2 74515659 cg19656282 Island 1174;2195;2099 2 7 17 None
74515882 cg07203423 Island 1397;2322 2 7 21
35 CPXM1 20 2800595 cg22304612 Island 43 2 7 17 None
2800616 cg07113642 Island 22 2 7 17
35a - 21 36693224 cg00495860 Island - 2 7 16 None
36693747 cg10445315 Island - 2 7 16
36 NR1I2 3 119810109 cg00836482 Island 27398;29624;29624;28073;-968 2 7 18 None
119810301 cg25562664 Island 27590;29816;29816;28265;-776 2 7 16
37 ZIC1 3 147419360 cg02232208 Island 25937 2 7 17 None
147419393 cg15873149 Island 25970 2 7 18
38 UCHL1 4 41256893 cg07068756 Island 59;-16;-54;123;-41;-40;-48;-19;-53;479;-165;-171 2 7 16 None
41256918 cg16142306 Island 84;9;-29;148;-16;-15;-23;6;-28;504;-190;-196 2 7 16
39 BEND4 4 42151678 cg02781618 Island 1201;1201;506 2 7 19 None
42151691 cg24657817 Island 1188;1188;493 2 7 17
40 OLIG3 6 137493591 cg01972751 Island 660 2 7 16 None
137493823 cg12744820 Island 428 2 7 16
41 HOXA-AS3 7 27152437 cg10739556 S_Shore 22459;5273;12072;4953;2384;145;125;162 2 7 17 None
27152442 cg24398479 S_Shore 22464;5278;12077;4958;2389;140;120;157 2 7 18
42 NPTX2 7 98616689 cg13314145 Island -609 2 7 19 Amplification
98616694 cg08315202 Island -604 2 7 20
*According to human genome assembly hg38.
**According to studies with reference number [27] and [28].
Gene symbol* Primer Primer sequence Length (bp) Annealing temprature (°C) Sequencing primer Sequencing primer sequence Sequencing to analyze
SIM1 Forward Biotine-GGTTTAGAGGGTAGTAAGATTTAGAGTT 334 54 Reverse ACCAATAAAACTAAATAACA CRAATCRACC CCRAACC
Reverse AACTACCCCCCCTAACTTCTTTATA
MIR129-2 Forward GGAGATAGAGGGATAGGATAGGTAG 274 54 Forward AGGAGTGGTGAGATTGA GTYGYGATGG AAYGYGTTGG GGAGATTTAG
Reverse ACCCTAAAACCAAACAAACTAAATC-Biotine
NR1I2 Forward TTTTTATTTTTTTATAGGAGGGTTATGA 492 54 Forward TGTTTTTTTAGGAAGGG YGTTTGYGAG ATTATT
Reverse CTACCCCCAAATATAATTTCAAACC-Biotine
HOXB-AS4 Forward GGAAAGATGTAAAAAATGGAGGTTAT 458 54 Forward TGTAGGTGGAGGTTTTTA GTTTTTGTYG GGYGYGGGTT GGGTTAG
Reverse AATAAAACTTCACCCTATTAATAAACTTCAA-Biotine
*According to human genome assembly hg38.
Supplementary Table 4. Conditions for PCR for bisulfite pyrosequencing 
Tumor sample ID Coverage Variant frequencies (%) Nucleotide change Amino acid change
4T 13451 12.8 c.183A>T p.Gln61His
9T1 7741 45.4 c.38G>A p.Gly13Asp
9T2 16340 32.8 c.38G>A p.Gly13Asp
12T 6869 37.6 c.35G>A p.Gly12Asp
20T 4789 9.9 c.34G>C p.Gly12Arg
26T 6360 6.7 c.34G>C p.Gly12Arg
27T 7219 6.6 c.35G>A p.Gly12Asp
28T1 6230 20.6 c.35G>A p.Gly12Asp
28T2 7558 45.9 c.35G>A p.Gly12Asp
35T1 6839 38.7 c.35G>A p.Gly12Asp
35T2 6861 3.3 c.35G>A p.Gly12Asp
35T3 5510 37.6 c.35G>A p.Gly12Asp
48T 11683 16.0 c.35G>A p.Gly12Asp
52T 9392 4.5 c.35G>T p.Gly12Val
53T 7326 25.1 c.35G>A p.Gly12Asp
60N 6460 4.2 c.35G>T p.Gly12Val
60T 6249 13.8 c.35G>T p.Gly12Val
62T 7330 15.8 c.35G>A p.Gly12Asp
64T 1360 10.4 c.34G>C p.Gly12Arg
75T 1600 17.4 c.35G>A p.Gly12Asp
Supplementary Table 5.  KRAS  mutations detected in 19 tumor samples and one non-tumurous sample
Tumor sample Gene Coverage Variant frequencies (%) Nucleotide change Amino acid change
22T CDKN2A 2558 15.5 c.45G>A p.Trp15*
23T ALK 3798 12.4 c.3707G>A p.Gly1236Asp
SMO 145 12.4 c.592G>T p.Val198Phe
CCND1 2239 11.3 c.674C>T p.Ser225Phe
CCND1 2279 11.2 c.677A>C p.Tyr226Ser
Supplementary Table 6.  Somatic mutations detected in the two tumor samples without KRAS  mutations but with substantial methylation levels
